Trial Profile
Assessment of Post Booster Antibody Responses in UK Infants Given a Reduced Priming Schedule of Meningococcal Serogroup B and 13 Valent Pneumococcal Conjugate Vaccines
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2021
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Rotavirus vaccine (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Meningococcal group B infections; Rotavirus infections
- Focus Pharmacodynamics
- Acronyms Sched3
- 17 Sep 2021 Status changed from active, no longer recruiting to completed.
- 08 Jan 2021 Planned End Date changed from 1 Jan 2019 to 1 Jun 2021.
- 24 Oct 2020 Results assessing comparison between conventional and novel (continuous) methods of monitoring temperature and evaluate any association between reactogenicity and the monocyte activation test published in the Vaccine